Every material Form 8-K Sunshine Biopharma Inc. has filed with the SEC since August 28, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Sunshine Biopharma (SBFM) closed a best-efforts public offering on October 9, 2026, with gross proceeds of approximately $6.0 million before placement agent fees and other expenses. The offering included Series D warrants with a $0.66 exercise price, which the company says could bring up to about $14.4 million more if fully exercised, though no assurance is given that any warrants will be exercised.
Common units sold at $0.55 each, with each unit including one share of common stock and two Series D warrants exercisable at $0.66 per share over five years.
Placement agent Aegis Capital Corp. received a 7% fee on the public offering price plus a 1% non-accountable expense allowance.
The company expects to use net proceeds for general corporate purposes and working capital.
The offering was made under a Form S-1 (File No. 333-299274) declared effective on October 7, 2026.
Sunshine Biopharma said that recent sales of its common stock under its at-the-market offering triggered a reduction in the exercise price of its outstanding Series B Warrants to $1.2046. The price is subject to further adjustment under the warrant terms. The change lowers the price at which warrant holders can buy shares, which could increase potential dilution for existing shareholders.
Series B Warrant exercise price reduced to $1.2046 per share
Reduction tied to recent sales of common stock under the at-the-market offering
Exercise price remains subject to further adjustment under the Series B Warrant terms
Sunshine Biopharma director Dr. Andrew Keller notified the company on August 25, 2026, that he will not seek or accept reelection when his current term ends at the next annual shareholder meeting. The filing discloses no reason for the departure and no financial results, so it is a board-composition change with no stated direct financial effect.
Director Dr. Andrew Keller notified the company on August 25, 2026.
Keller will not seek or accept reelection when his current term expires.
His term ends at the company's next annual shareholder meeting.
The 8-K was signed by CEO Dr. Steve N. Slilaty on August 28, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Sunshine Biopharma Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →